Frontlight ResearchEarly access
Active, not recruitingPhase 2
Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD
Key facts
- Who runs it
- Unity Health Toronto
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 15 people, planned
- Started
- 1 Jun 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional
- Treatments tested
- Psilocybin
- Record updated
- 6 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist
- Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms
- Are willing to refrain from taking any psychiatric medications during the study period
Who cannot take part
- Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment
- Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder
- Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration
- Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions
- History of seizure disorder
- Uncontrolled insulin-dependent diabetes
- Recent stroke, intracranial or subarachnoid hemorrhage (< 1 year from signing of informed consent form [ICF]), recent myocardial infarction (< 1 year from signing of ICF), clinically significant arrhythmia (< 1 year from signing of ICF)
- Lifetime history of substance-induced psychosis
- Lifetime history of substance use disorder with a hallucinogen
- History of alcohol use disorder in the past 3 months
- Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).
The group in the trial
- ExperimentalTreatment being tested
Single dose of psilocybin 25mg + Massed cognitive processing therapy
Treatment: Psilocybin
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial
- Publications
- Record updated
- 6 October 2026